Skip to content

Study · Case report or series · n = 2 · 1983

5 results

Effect of a synthetic thymic factor (facteur thymique serique) on natural killer cell activity in humans.

Dokhelar MC, Tursz T, Dardenne M, Bach JF

International journal of immunopharmacology1 Jan 1983Cited by 9 (Europe PMC)

PMID6195118 (opens in a new tab)DOI10.1016/0192-0561(83)90029-2 (opens in a new tab)PepBankPUB-06195118
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesActivity measurement

    In two cancer patients with low pretreatment activity, FTS progressively increased peripheral natural killer activity.

    In plain wordsIn two cancer patients with low initial activity, FTS increased peripheral natural killer activity compared with pretreatment.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    IncreaseNatural killer activity
    Study

    n = 2

    Comparator
    Pretreatment
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    10 micrograms/kg every 3 days · intravenousAs given in this study (human).

    Source sentences

    Summary
    When administered in vivo to 4 cancer patients (10 micrograms/kg i.v. every 3 days), FTS progressively increased peripheral NK activity in two patients with low pre-treatment NK values,
    1 context sentence
    Summary · context
    NK cell activity was measured in a 51Chromium-release assay in which effector cells were peripheral blood lymphocytes (PBL) or bone marrow (BM) lymphocytes from healthy individuals and patients, and targets were K562 cells.
  2. 02HumanCase report or seriesActivity measurement

    In two cancer patients with normal or high pretreatment activity, FTS decreased peripheral natural killer activity.

    In plain wordsIn two cancer patients with normal or high initial activity, FTS decreased natural killer activity compared with pretreatment.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseNatural killer activity
    Study

    n = 2

    Comparator
    Pretreatment
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    10 micrograms/kg every 3 days · intravenousAs given in this study (human).

    Source sentences

    Summary
    whereas it decreased NK activity in two patients with previously normal or high NK values.
    2 context sentences
    Summary · context
    When administered in vivo to 4 cancer patients (10 micrograms/kg i.v. every 3 days),
    Summary · context
    NK cell activity was measured in a 51Chromium-release assay in which effector cells were peripheral blood lymphocytes (PBL) or bone marrow (BM) lymphocytes from healthy individuals and patients, and targets were K562 cells.
  3. 03LabEx vivo tissueActivity measurement

    In normal human peripheral blood lymphocytes, low-concentration FTS increased natural killer activity.

    In plain wordsIn lab tests, low-concentration FTS increased natural killer activity in normal human blood lymphocytes.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    IncreaseNatural killer activity
    Study

    humann: not reported in source

    normal peripheral blood lymphocytes
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    10(-2) ng/mlAs given in this study (human).

    Source sentences

    Summary
    Low concentrations of FTS (10(-2) ng/ml) increased NK activity (P less than 0.001)
    1 context sentence
    Summary · context
    NK cell activity was measured in a 51Chromium-release assay in which effector cells were peripheral blood lymphocytes (PBL) or bone marrow (BM) lymphocytes from healthy individuals and patients, and targets were K562 cells.
  4. 04LabEx vivo tissueActivity measurement

    In normal human peripheral blood lymphocytes, higher-concentration FTS decreased natural killer activity.

    In plain wordsIn lab tests, higher-concentration FTS decreased natural killer activity in normal human blood lymphocytes.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseNatural killer activity
    Study

    humann: not reported in source

    normal peripheral blood lymphocytes
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    10 and 10(2) ng/mlAs given in this study (human).

    Source sentences

    Summary
    whereas higher concentrations decreased it (P less than 0.01) for 10 and 10(2) ng/ml.
    2 context sentences
    Summary · context
    When added in vitro in this assay, FTS modulated NK cell activity of normal PBL.
    Summary · context
    NK cell activity was measured in a 51Chromium-release assay in which effector cells were peripheral blood lymphocytes (PBL) or bone marrow (BM) lymphocytes from healthy individuals and patients, and targets were K562 cells.
  5. 05LabEx vivo tissueActivity measurement

    In human bone marrow lymphocytes, FTS had no effect on natural killer activity.

    In plain wordsIn lab tests, FTS did not change natural killer activity in human bone marrow lymphocytes.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    No significant changeNatural killer activity
    Study

    humann: not reported in source

    bone marrow lymphocytes
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    FTS exhibited no effect on NK cell activity of BM lymphocytes.
    1 context sentence
    Summary · context
    NK cell activity was measured in a 51Chromium-release assay in which effector cells were peripheral blood lymphocytes (PBL) or bone marrow (BM) lymphocytes from healthy individuals and patients, and targets were K562 cells.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.